MedVadis Research Corp
Welcome,         Profile    Billing    Logout  
 1 Trial 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Spierings, Egilius LH
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
01/25
01/25
O'Brien, Jessica
NCT05531526: Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

Recruiting
3
1150
Europe, US, RoW
AR1001, Placebo
AriBio Co., Ltd.
Alzheimer Disease
12/25
12/27
Counihan, Donald
NCT04743141: Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Recruiting
3
200
Europe, US
Rimegepant / BHV3000
Pfizer
Acute Treatment of Migraine
12/24
05/27
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Active, not recruiting
3
1083
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
05/25
05/25
NCT04649242 / 2020-003517-35: Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Recruiting
3
2100
Europe, Canada, Japan, US, RoW
Rimegepant/BHV3000, Matching placebo
Pfizer
Pediatric Migraine
10/26
07/31
NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Terminated
2/3
535
US
BHV-3500 (zavegepant), Placebo
Pfizer
Migraine
03/24
03/24

Download Options